
Horizon Therapeutics has announced that its IGF-1R inhibitor Tepezza (teprotumumab-trbw) has become the first and only therapy approved by the …
Boyds expands Regulatory Affairs team to support growing demand
Sterling doubles ADC manufacturing capacity at Welsh facility
Femtosecond laser cuts lung tumour margin assessment time
Blood sensor detects Parkinson’s-associated proteins in 40 minutes

